Solventum Co. (NYSE:SOLV) is Mayar Capital Ltd.'s 10th Largest Position

Mayar Capital Ltd. grew its position in Solventum Co. (NYSE:SOLV - Free Report) by 187.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,290 shares of the company's stock after purchasing an additional 19,739 shares during the period. Solventum makes up approximately 2.6% of Mayar Capital Ltd.'s holdings, making the stock its 10th largest holding. Mayar Capital Ltd.'s holdings in Solventum were worth $2,001,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Modus Advisors LLC bought a new stake in Solventum in the fourth quarter valued at $25,000. Stonebridge Financial Group LLC purchased a new position in shares of Solventum during the fourth quarter valued at $26,000. Crews Bank & Trust purchased a new stake in Solventum in the 4th quarter worth approximately $32,000. True Wealth Design LLC grew its position in Solventum by 23,550.0% in the third quarter. True Wealth Design LLC now owns 473 shares of the company's stock worth $33,000 after acquiring an additional 471 shares in the last quarter. Finally, Prospera Private Wealth LLC bought a new position in shares of Solventum in the third quarter valued at approximately $35,000.

Analyst Upgrades and Downgrades

SOLV has been the topic of a number of analyst reports. The Goldman Sachs Group upped their price target on Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a research report on Monday, March 3rd. Wells Fargo & Company boosted their price target on shares of Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Friday, February 28th. Morgan Stanley boosted their price target on Solventum from $73.00 to $80.00 and gave the stock an "equal weight" rating in a research report on Wednesday, March 5th. Mizuho upped their price target on shares of Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a research note on Monday, March 3rd. Finally, Piper Sandler upped their price objective on shares of Solventum from $75.00 to $84.00 and gave the stock a "neutral" rating in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, Solventum presently has an average rating of "Hold" and an average target price of $79.86.

Remove Ads

Solventum Stock Down 2.6 %

SOLV stock traded down $1.94 during trading on Wednesday, reaching $73.95. 1,042,167 shares of the stock were exchanged, compared to its average volume of 1,439,125. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The firm's 50 day moving average is $74.08 and its 200 day moving average is $70.94. The firm has a market cap of $12.79 billion and a P/E ratio of 26.89. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $85.92.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.